Evidence Gaps

What do systematic reviews say?

1 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + DPP4‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + DPP4‐I compared with metformin plus another antidiabetic drug (very low certainty).

3 findings from 1 review

Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
RR 2.21 [0.74, 6.58]
4 studies · 5093 participants
Very low
Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Very low
Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
RR 1.32 [0.76, 2.28]
9 studies · 11694 participants
Low